Scancell Holdings PLC on Monday reported a positive response in its ’Covidity’ trial, which aims to deliver needle-free injectable Covid vaccines.
The Nottingham, England-based cancer immunotherapies developer said its Covid vaccine candidates induced neutralising antibodies in previously infected patients, previously vaccinated patients and ’naïve’ patients — those never confirmed to have had Covid and who are not vaccinated.
The needle-free injection is via a PharmaJet device, which delivers a vaccine or a medicine via a narrow fluid stream. PharmaJet is a Colorado, US-based medical technology company.
Scancell added that the trial validates that ‘AvidiMab-modified immunotherapies boost immune responses and PharmaJet’s needle-free injection device is effective in delivering immunobody-generated drug candidates.’
Chief Executive Officer Lindy Durrant said: ‘The success of a human trial demonstrating that an AvidiMab modified DNA vaccine, delivered via a needle free injection, can induce both T cell and antibody responses, with no safety concerns, is a pivotal proof point for Scancell’s clinical strategy.
The company added that it will now seek a partner to progress the Covidity vaccine programme.
Scancell shares were 5.0% higher at 19.17 pence each in London on Monday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
